We also showed that IL-6 reduced the efficacy of MTX via the inhibition of SLC19A1 expression; therefore, IL-6 inhibition may improve responsiveness to MTX in patients with RA who show inadequate response to MTX. Here, SLC19A1 is linked to rheumatoid arthritis.